Pharmaceutical industry warns of austerity measures

Germany's research-based pharmaceutical industry is significantly concerned about upcoming austerity measures targeting the public health insurance system (GKV). Industry representatives argue that the proposed cuts are partly a result of the federal government not meeting its financial obligations.

Oliver Kirst, chairman of the German Association of Pharmaceutical Industry (BPI), criticized the government's approach. "Our healthcare system does not have a financing problem; it has an efficiency problem," Kirst stated, emphasizing the need for structural reforms rather than austerity.

According to BPI's calculations, the pharmaceutical industry is expected to shoulder nearly a quarter (24.5%) of the total savings to be generated by GKV between 2027 and 2030. This proportion is disproportionately high, given that the pharmaceutical sector represents only about 9% of GKV's expenditures. The industry already contributes significant annual rebates to stabilize GKV's finances.

Studies suggest that austerity in pharmaceutical pricing could lead to substantial indirect economic losses for the country. For instance, innovative medicines allow patients with severe illnesses like cancer or multiple sclerosis to work longer, contributing to economic productivity. The health industry (iGW) is a significant contributor to the German economy, with growth rates historically surpassing the overall economy.

The pharmaceutical sector advocates for viewing healthcare spending as an investment rather than mere cost. Innovative treatments extend life expectancy and enable longer working lives, benefiting both individuals and the national economy. The industry hopes that legislative actions planned for the fall will bolster research and production within Germany.